GRANULOTsITARNYE KOLONIESTIMULIRUYuShchIE FAKTORY: SKhODSTVO I RAZLIChIYa


如何引用文章

全文:

详细

Проведение химиотерапии длительное время ограничивалось ее гематологической токсичностью. Применение гемопоэтических ростовых факторов, в частности гранулоцитарного колониестимулирующего фактора (Г-КСФ), позволило увеличить дозы цитотоксических препаратов и повысить эффективность химиотерапии. Представлены результаты исследований, посвященных изучению свойств и эффективности препаратов Г-КСФ ленограстима и филграстима, являющихся соответственно гликозилированной и негликозилированной формами Г-КСФ. Проведенные клинические исследования продемонстрировали значимость гликозилирования как для эффективности, так и для качества ответа на препарат, что подтверждают и отчасти объясняют преимущества ленограстима (Граноцита) перед филграстимом.

全文:

受限制的访问

作者简介

S. Semochkin

参考

  1. Bodey G.P, Buckley Y, Sathe Y.S, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia, Ann Intern Med 1966;64:328-40.
  2. Гершанович М.Л. Осложнения при химио- и гормонотерапии злокачественных опухолей. М., 1982.
  3. Klastersky J. Current attitudes for therapy for febrile neutropenia with. Consideration to cost-effectiveness. Curr Opinion Oncol 1998;10:284-90.
  4. Lopez A, et al. Blood 2006;108:475b, abstr. 5512.
  5. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
  6. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991;325:164-70.
  7. Souza L.M, Воопе Т.С, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232:61-65.
  8. Oh-Eda M, Hasegawa M, Hattori К, et al. 0-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990;265:11432-35.
  9. Ono M. Physicochemical and biochemical characteristics of gly-cosylated recombinant human granulocyte colony-stimulating factor (lenograstim). Eur J Cancer 1994; 30A(Suppl. 3):7-11.
  10. Wang С, Eufemi M, Turano C, et al. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996;35: 7299-07.
  11. Arakawa T, Prestrelski S.J, Narhi L.O, et al. Cysteine 17 of recombinant human granulocyte colony-stimulating factor is partially solvent-exposed. J Protein Chem 1993; 12:525-31.
  12. Nissen С. Glycosylation of recombinant human granulocyte colony-stimulating factor: implications for stability and potency. Eur J Cancer 1994;30A(Suppl. 3):12-14.
  13. Oh-Eda M, Hasegawa M, Hattori К, et al. 0-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990;265:11432-35.
  14. Ono M. Physicochemical and biochemical characteristics of gly-cosylated recombinant human granulocyte colony-stimulating factor (lenograstim). Eur J Cancer 1994; 30A(Suppl. 3):7-11.
  15. Gisselbrecht С, Haioun C, et al. Placebo -controlled phase III study of Lenograstim (glycosylated recombinant human granulocyte coloni - stimulating factor) in aggressive non - Hodgkin's lyphoma factor factor influencing chemotherapy administration. Leuk Lymphoma 1997;25(3-4):289-300.
  16. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim Prevents Morbidity From Intensive Induction Chemotherapy in the Treatment of Inflammatory Breast Cancer. J Clin Oncol 1995;13(7):1564-71.
  17. Nissen C, Carbonare D, Moser Y. In vitro comparison of the biological potency of glycosylated versus non-glycosylated rG-CSF. Drug Invest 1994;7:346-52.
  18. Venditti A, Battaglia A, Del Poeta G, et al. Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods. Bone Marrow Transplant 1999;24:1019-2 7.
  19. Fourcade M. Human recombinant granulocyte colony stimulating factors: glycosylation makes the difference. La Presse Medicate 1997;26:1460-62.
  20. Watts M.J, Sullivan A.M, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor, an analysis of progenitorcell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. Clin Oncol 1997;15:535-46.
  21. Linch D. Activity in clinical settings: comparison of PBPC mobilization with different rG-CSFs in patients with lymphoma. Int J Hematol 1996;64(Suppl. 2):29.
  22. Hoglund M, Smedmyr B, Totterman T.H, et al. Mobilization of CD34+ cells by glycosylated and non-glycosylated G-CSF in healthy volunteers: a comparative study. Eur J Haematol 1997;59:177-83.
  23. Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) - what is the difference? Meet Oncol 1998;15: 229-33.
  24. Ataergin S, Arpaci F, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: A randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008;83(8):644-48.
  25. Aviles A, Guzman R, Garcia E.L, et al. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs 1996;7(4):392-97.
  26. Garcia-Carbonero R, Mayordomo J.I, Tornamira M.V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial. J Natl Cancer Inst 2001;93:31 -38.
  27. Clark O.A, Lyman G.H, Castro A.A, et al: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A metaanalysis of randomized controlled trials. J Clin Oncol 2005;23:4198-214.
  28. Kitagawa S, You A, Souza L.M, et al. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by chemotactic peptide. Biochem Biophys Res Commun 1987;144:1143-46.
  29. Yong K.L, Linch D.C. Differential effects of granulocyte- and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol 1992;49:251-59.
  30. Weisbart R.H, Kacena A, Schuh A, et al. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988;332:647-48.
  31. Spertini O, Kansas G.S, Munro J.M, et al. Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature 1991; 349:691-94.
  32. Liles W.C, Rodger E.R, Dale D.C. Differential regulation of human neutrophil surface expression of CD14, CD11b, CD18, and L-selectin following the administration of G-CSF in vivo and in vitro. Clin Res 1994;42:304A.
  33. Ohsaka A, Saionji K, Sato N, et al. Granulocyte-colony stimulating factor down-regulates the surface expression of the human leukocyte adhesion molecule-1 on human neutrophils in vitro and in vivo. Br J Haematol 1993;84:574-80.
  34. Nathan C.F. Respiratory burst in adherent human neutrophils: Triggering by colony-stimulating factors CSF-GM and CSF-F. Blood 1989;73:301-06.
  35. Valerius T, Repp R, de Wit T.P.M, et al. Involvement of the high-affinity receptor for IgG (FcgR1; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993;82:931-39.
  36. Yamamoto Y, Klein T.W, Friedman H, et al. Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol Med Microbiol 1993;7:15-22.
  37. Carulli Gi, Mattii L, et al. Actin polymerization in neutrophils from donors of peripheral blood stem cells: Divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor. Am J Hematology 2006; 81 (Is 5):318-323.
  38. Ribeiro D, Veldwijk M.R, Benner A, et al. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion 2007;47(6):969-80.
  39. Liliu H, Le Pen C. Evaluation of treatment costs with recombinant human granulocyte colony stimulating factors in mobilization of stem cells. J Pharm Clin 1999;18:277-81.
  40. Debrix I, Ait Ben Ali S, Lotz J.P, et al. Economic evaluation of use of two granulocytecolony-stimulating factors in patients treated intensive chemotherapy. Eur Hosp Pharm 1999;5:24-28.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2009
##common.cookie##